What is Zacks Research's Estimate for Omnicell Q3 Earnings?

Omnicell, Inc. (NASDAQ:OMCL - Free Report) - Investment analysts at Zacks Research lowered their Q3 2025 EPS estimates for shares of Omnicell in a research note issued on Wednesday, February 26th. Zacks Research analyst R. Department now anticipates that the company will post earnings per share of $0.23 for the quarter, down from their previous forecast of $0.31. The consensus estimate for Omnicell's current full-year earnings is $1.09 per share. Zacks Research also issued estimates for Omnicell's Q4 2025 earnings at $0.38 EPS, FY2025 earnings at $0.81 EPS, Q3 2026 earnings at $0.24 EPS, Q4 2026 earnings at $0.36 EPS and FY2026 earnings at $1.08 EPS.

Several other analysts have also weighed in on the stock. JPMorgan Chase & Co. boosted their target price on shares of Omnicell from $37.00 to $44.00 and gave the company a "neutral" rating in a research note on Thursday, November 21st. Benchmark restated a "buy" rating and set a $62.00 price objective on shares of Omnicell in a research note on Tuesday, February 4th. StockNews.com cut Omnicell from a "buy" rating to a "hold" rating in a research note on Tuesday, December 10th. Wells Fargo & Company reduced their price target on shares of Omnicell from $49.00 to $40.00 and set an "equal weight" rating for the company in a report on Monday, January 13th. Finally, Bank of America dropped their price objective on shares of Omnicell from $54.00 to $46.00 and set a "neutral" rating on the stock in a report on Monday, January 6th. Five analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $52.33.

Omnicell Stock Performance

Shares of NASDAQ OMCL traded down $0.33 during trading on Monday, reaching $37.73. The stock had a trading volume of 537,802 shares, compared to its average volume of 412,395. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.22 and a current ratio of 1.37. The stock has a market cap of $1.75 billion, a PE ratio of 139.75, a P/E/G ratio of 7.53 and a beta of 0.78. Omnicell has a one year low of $25.12 and a one year high of $55.74. The firm's 50 day moving average price is $42.39 and its two-hundred day moving average price is $43.83.

Omnicell (NASDAQ:OMCL - Get Free Report) last posted its quarterly earnings results on Thursday, February 6th. The company reported $0.45 EPS for the quarter, missing analysts' consensus estimates of $0.57 by ($0.12). Omnicell had a return on equity of 3.82% and a net margin of 1.13%.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in OMCL. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in Omnicell by 22.4% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 119,181 shares of the company's stock worth $5,306,000 after purchasing an additional 21,847 shares in the last quarter. Squarepoint Ops LLC lifted its stake in Omnicell by 286.4% during the fourth quarter. Squarepoint Ops LLC now owns 149,717 shares of the company's stock valued at $6,665,000 after purchasing an additional 110,966 shares during the last quarter. Two Sigma Investments LP boosted its holdings in Omnicell by 44.2% during the fourth quarter. Two Sigma Investments LP now owns 141,738 shares of the company's stock worth $6,310,000 after buying an additional 43,471 shares in the last quarter. Toronto Dominion Bank acquired a new position in Omnicell in the fourth quarter worth approximately $30,637,000. Finally, Point72 Hong Kong Ltd bought a new position in shares of Omnicell in the fourth quarter valued at $101,000. 97.70% of the stock is currently owned by institutional investors.

Insider Activity at Omnicell

In other Omnicell news, Director Mark W. Parrish sold 12,000 shares of the firm's stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $47.30, for a total transaction of $567,600.00. Following the transaction, the director now owns 58,427 shares of the company's stock, valued at approximately $2,763,597.10. This trade represents a 17.04 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 2.64% of the company's stock.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.